Nebiloc (Nebivolol)

Nebivolol, the active ingredient in Nebiloc, is a beta blocker presented as a tablet (various strengths) for oral use. It treats hypertension and heart failure in adult patients. GNH USA supplies Nebiloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is indicated for conditions within the cardiovascular disease pathway, primarily to control blood pressure and support cardiac function.

Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. Heart failure: improves left‑ventricular ejection fraction and reduces symptoms of chronic heart failure. High cardiovascular risk: may be used as part of a risk‑reduction strategy when indicated by a physician.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness. - Nasal congestion or rhinorrhea. - Nausea or mild gastrointestinal upset. - Bradycardia: heart rate slower than normal.

Serious or Rare Side Effects: - Severe bradycardia or heart block. - Marked hypotension leading to fainting. - Bronchospasm in patients with asthma or COPD. - Allergic reactions such as rash, pruritus, or angio‑edema. - Hepatic dysfunction or elevated liver enzymes. - Acute heart failure decompensation.

Nebivolol requires careful monitoring and patient education before and during therapy.

Monitor blood pressure: ensure target levels are achieved without excessive drop. Assess heart rate: watch for bradycardia, especially in patients with conduction disorders. Use caution in asthma/COPD: β1‑selectivity reduces but does not eliminate risk of bronchospasm. Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. Adjust dose in renal impairment: consider reduced dosing in severe renal dysfunction. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Other β‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): increased risk of AV block. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol plasma levels. - Combined antihypertensives (e.g., ACE inhibitors, ARBs) in high doses: may cause severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure. - Digoxin: watch for bradyarrhythmias. - NSAIDs: may blunt antihypertensive effect. - Clonidine: risk of rebound hypertension if stopped abruptly. - Antidiabetic agents: monitor glucose as β‑blockade can mask hypoglycemia symptoms.